Insuman Comb 15 (Insulin Human)

Insulin Human binds to insulin receptors on muscle, fat, and liver cells, activating intracellular signaling that moves glucose transporters to the cell surface. This increases glucose uptake from the bloodstream and reduces hepatic glucose production, thereby lowering circulating blood glucose concentrations.

The dose of Insuman Comb 15 is individualized and set by a qualified prescriber based on the patient’s blood glucose readings, dietary intake, activity level, and overall treatment goals. Patients should follow the dosing instructions provided by their healthcare professional.

Insuman Comb 15 is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy or lactation only if the potential benefits justify the potential risks, and under close medical supervision.

To order Insuman Comb 15, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Insuman Comb 15 contains human insulin, which has a similar efficacy profile to other recombinant human insulins but differs from insulin analogues that may have altered onset or duration of action. Choice of product depends on individual patient needs, dosing flexibility, and prescriber preference.

Insuman Comb 15 should be stored at 2‑8 °C (refrigerated) in its original carton, protected from light. Do not freeze or shake the vial. Once in use, the product may be kept at room temperature (up to 30 °C) for a limited period as indicated on the label.

Insuman Comb 15 is administered by subcutaneous injection into the abdomen, thigh, or upper arm. The injection technique, site rotation, and timing relative to meals should follow the prescribing clinician’s instructions to ensure optimal absorption and glycemic control.

The most serious risks include severe hypoglycemia, which can cause confusion, seizures, or loss of consciousness, and allergic reactions ranging from rash to anaphylaxis. Patients should be educated on early signs of hypoglycemia and instructed to seek immediate medical attention for any severe allergic symptoms.

Insuman Comb 15 should not be used by individuals with a known hypersensitivity to human insulin or any of the excipients in the formulation. It is also contraindicated in patients with severe hypoglycemia unawareness or those for whom insulin therapy is not indicated by their healthcare provider.